Describe a situation where you had to mediate a disagreement between a pharmaceutical sponsor and the clinical site's research team regarding data interpretation or protocol amendments. How did you facilitate communication and reach a resolution that satisfied both parties while maintaining regulatory compliance?
final round · 4-5 minutes
How to structure your answer
Employ the CIRCLES method for conflict resolution. 1. Comprehend the situation: Identify core issues and differing perspectives. 2. Isolate the key problems: Distinguish between data interpretation discrepancies and protocol amendment concerns. 3. Root causes: Determine underlying reasons for disagreement (e.g., miscommunication, differing scientific opinions, resource constraints). 4. List solutions: Brainstorm potential resolutions collaboratively. 5. Evaluate trade-offs: Assess impact of each solution on data integrity, patient safety, and regulatory compliance. 6. Select the best option: Propose a mutually agreeable path forward. 7. Explain and implement: Clearly communicate the chosen resolution and oversee its execution, ensuring all parties understand and adhere to regulatory guidelines and ICH-GCP principles.
Sample answer
I leverage the CIRCLES method to navigate such complex situations. In one instance, a pharmaceutical sponsor interpreted preliminary efficacy data differently than our site's principal investigator, leading to a proposed protocol amendment that the PI felt was premature and potentially harmful to patient safety. I first comprehended both perspectives, identifying the core disagreement stemmed from differing statistical interpretations and risk tolerance. I isolated the key problems: data interpretation versus patient welfare. We then delved into root causes, which included a lack of clarity in the initial statistical analysis plan. I facilitated a joint meeting where both sides presented their data and rationale, ensuring all discussions adhered to ICH-GCP and regulatory guidelines. I listed potential solutions, including a third-party statistical review or a phased amendment. After evaluating trade-offs, we selected a compromise: a revised amendment that incorporated a more conservative approach to dose escalation, coupled with an independent statistical review of the preliminary data. This resolution satisfied both parties, maintained regulatory compliance, and ensured patient safety, ultimately preventing a 15% increase in projected study costs due to potential protocol deviations.
Key points to mention
- • Specific trial phase and therapeutic area.
- • Clear identification of the conflicting parties and their core disagreements.
- • Demonstration of structured communication facilitation (e.g., tripartite meeting, agenda setting).
- • Understanding of regulatory frameworks (e.g., ICH E6 R2, 21 CFR Part 312, IRB requirements).
- • Ability to propose and negotiate a mutually acceptable, compliant solution.
- • Emphasis on data integrity and patient safety as guiding principles.
- • Documentation and communication of the resolution.
Common mistakes to avoid
- ✗ Failing to identify the root cause of the disagreement.
- ✗ Taking sides or demonstrating bias towards one party.
- ✗ Proposing solutions that violate regulatory guidelines.
- ✗ Not involving all key stakeholders in the resolution process.
- ✗ Lack of follow-up or documentation of the agreed-upon resolution.
- ✗ Focusing solely on the 'what' without explaining the 'how' (process).